SILICOPHARM, INC. – Trademark Portfolio

Entity Type: 03

SILICOPHARM, INC. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include KNOCKG. The owner is based in DAEGU.

#507, 333 TECHNO JUNGANG-DAERO, HYEONPUNG-EUP, DALSEONG-GUN

DAEGU 42988 , KR

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

KNOCKG
KNOCKG
Registered 2021

Trademark Classifications

SILICOPHARM, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does SILICOPHARM, INC. have?

SILICOPHARM, INC. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does SILICOPHARM, INC. file in?

SILICOPHARM, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.

What are SILICOPHARM, INC.'s most well-known trademarks?

SILICOPHARM, INC.'s registered trademark portfolio includes well-known marks such as KNOCKG. These are among 1 currently registered trademark in the portfolio.

What is SILICOPHARM, INC.'s trademark registration success rate?

SILICOPHARM, INC. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.